Olaparib
VIDEO: OlympiA trial shows olaparib’s benefits for patients with BRCA mutations ‘persist’
SAN ANTONIO — In this video, Halle Moore, MD, discusses the long-term results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.
VIDEO: OlympiA trial shows ‘continued benefit’ in breast cancer survival
SAN ANTONIO — In this video, Judy Garber, MD, MPH, discusses the results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.
Olaparib confers durable benefit in BRCA-mutated breast cancer
SAN ANTONIO — One year of adjuvant olaparib after standard treatment improved outcomes compared with placebo among patients with high-risk BRCA-mutated breast cancer, according to data presented at San Antonio Breast Cancer Symposium.
Prostate Cancer updates: Test identifies aggressive disease, diet affects progression risk
National Prostate Cancer Awareness Month is observed every September.
Olaparib monotherapy ‘true paradigm shift’ in biochemically recurrent prostate cancer
Olaparib monotherapy may be an effective treatment option for certain men with biochemically recurrent prostate cancer, according to results of a nonrandomized phase 2 trial.
Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial
The combination of pembrolizumab and maintenance olaparib failed to significantly improve survival outcomes among adults with metastatic nonsquamous non-small cell lung cancer, according to the agent’s manufacturer.
SABCS recap: Novel regimens, treatment de-escalation and ‘catastrophic’ financial burdens
Pembrolizumab plus olaparib does not extend survival in triple-negative breast cancer
Ovarian cancer research at ESMO Congress explores chemotherapy-free treatment options
MADRID — This year’s ESMO Congress included research updates that provide valuable data on chemotherapy-free treatment options being explored in recurrent ovarian cancer.
Anticancer-drug dose changes, discontinuations lead to $4,290 in pill wastage per patient
Wastage from dose reduction or discontinuation of the most common oral anticancer drugs costs a mean of $4,290 per patient, results of a retrospective study showed.